Cassandra N Spracklen1, Caitlin J Smith1, Audrey F Saftlas1, Elizabeth W Triche2, Andrew Bjonnes3,4, Brendan J Keating5,6, Richa Saxena3,4, Patrick J Breheny7, Andrew T Dewan8, Jennifer G Robinson1, Josephine Hoh9, Kelli K Ryckman1. 1. a Department of Epidemiology , University of Iowa College of Public Health , Iowa City , Iowa , USA. 2. b Department of Epidemiology, Division of Biology and Medicine , Brown University , Providence , Rhode Island , USA. 3. c Center for Human Genetic Research and Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital , Boston , Massachusetts , USA. 4. d Program in Medical and Population Genetics, Broad Institute , Cambridge , Massachusetts , USA. 5. e Department of Surgery, Penn Transplant Institute, Perelman School of Medicine , University of Pennsylvania , Philadelphia , Pennsylvania , USA. 6. f Division of Genetics, The Children's Hospital of Philadelphia , Philadelphia , Pennsylvania , USA. 7. g Department of Biostatistics, University of Iowa College of Public Health , Iowa City , Iowa , USA. 8. h Division of Chronic Disease Epidemiology, Yale School of Public Health , New Haven , Connecticut , USA. 9. i Department of Environmental Health Sciences, Yale School of Public Health , New Haven , Connecticut , USA.
Abstract
OBJECTIVE: To examine the association between genetic predisposition to elevated C-reactive protein (CRP)and risk for preeclampsia using validated genetic loci for C-reactive protein. METHODS: Preeclampsia cases (n = 177) and normotensive controls (n = 116) were selected from live birth certificates to nulliparous Iowa women during the period August 2002-May 2005. Disease status was verified by the medical chart review. Genetic predisposition to CRP was estimated by a genetic risk score on the basis of established loci for CRP levels. Logistic regression analyses were used to evaluate the relationships between the genotype score and preeclampsia. Replication analyses were performed in an independent, US population of preeclampsia cases (n = 516) and controls (n = 1,097) of European ancestry. RESULTS: The genetic risk score (GRS) related to higher levels of CRP demonstrated a significantly decreased risk of preeclampsia (OR 0.89, 95% CI 0.82-0.96). When the GRS was analyzed by quartile, an inverse linear trend was observed (p = 0.0006). The results were similar after adjustments for the body mass index (BMI), smoking, and leisure-time physical activity. In the independent replication population, the association with the CRP GRS was also marginally significant (OR 0.97, 95% CI 0.92, 1.02). Meta-analysis of the two studies was statistically significant (OR 0.95, 95% CI 0.90, 0.99). CONCLUSION: Our data suggest an inverse, counterintuitive association between the genetic predisposition to elevated levels of CRP and a decreased risk of preeclampsia. This suggests that the blood CRP level is a marker of preeclampsia, but it does not appear to be a factor on the causal pathway.
OBJECTIVE: To examine the association between genetic predisposition to elevated C-reactive protein (CRP)and risk for preeclampsia using validated genetic loci for C-reactive protein. METHODS:Preeclampsia cases (n = 177) and normotensive controls (n = 116) were selected from live birth certificates to nulliparous Iowa women during the period August 2002-May 2005. Disease status was verified by the medical chart review. Genetic predisposition to CRP was estimated by a genetic risk score on the basis of established loci for CRP levels. Logistic regression analyses were used to evaluate the relationships between the genotype score and preeclampsia. Replication analyses were performed in an independent, US population of preeclampsia cases (n = 516) and controls (n = 1,097) of European ancestry. RESULTS: The genetic risk score (GRS) related to higher levels of CRP demonstrated a significantly decreased risk of preeclampsia (OR 0.89, 95% CI 0.82-0.96). When the GRS was analyzed by quartile, an inverse linear trend was observed (p = 0.0006). The results were similar after adjustments for the body mass index (BMI), smoking, and leisure-time physical activity. In the independent replication population, the association with the CRP GRS was also marginally significant (OR 0.97, 95% CI 0.92, 1.02). Meta-analysis of the two studies was statistically significant (OR 0.95, 95% CI 0.90, 0.99). CONCLUSION: Our data suggest an inverse, counterintuitive association between the genetic predisposition to elevated levels of CRP and a decreased risk of preeclampsia. This suggests that the blood CRP level is a marker of preeclampsia, but it does not appear to be a factor on the causal pathway.
Authors: Caitlin J Smith; Audrey F Saftlas; Cassandra N Spracklen; Elizabeth W Triche; Andrew Bjonnes; Brendan Keating; Richa Saxena; Patrick J Breheny; Andrew T Dewan; Jennifer G Robinson; Josephine Hoh; Kelli K Ryckman Journal: Am J Hypertens Date: 2015-05-23 Impact factor: 2.689
Authors: A J Buurma; R J Turner; J H M Driessen; A L Mooyaart; J W Schoones; J A Bruijn; K W M Bloemenkamp; O M Dekkers; H J Baelde Journal: Hum Reprod Update Date: 2013-01-08 Impact factor: 15.610
Authors: Audrey F Saftlas; Linda Rubenstein; Kaitlin Prater; Karisa K Harland; Elizabeth Field; Elizabeth W Triche Journal: J Reprod Immunol Date: 2013-08-15 Impact factor: 4.054
Authors: Cassandra N Spracklen; Audrey F Saftlas; Elizabeth W Triche; Andrew Bjonnes; Brendan Keating; Richa Saxena; Patrick J Breheny; Andrew T Dewan; Jennifer G Robinson; Josephine Hoh; Kelli K Ryckman Journal: Am J Hypertens Date: 2014-12-17 Impact factor: 2.689
Authors: Kiran Musunuru; Guillaume Lettre; Taylor Young; Deborah N Farlow; James P Pirruccello; Kenechi G Ejebe; Brendan J Keating; Qiong Yang; Ming-Huei Chen; Nina Lapchyk; Andrew Crenshaw; Liuda Ziaugra; Anthony Rachupka; Emelia J Benjamin; L Adrienne Cupples; Myriam Fornage; Ervin R Fox; Susan R Heckbert; Joel N Hirschhorn; Christopher Newton-Cheh; Marcia M Nizzari; Dina N Paltoo; George J Papanicolaou; Sanjay R Patel; Bruce M Psaty; Daniel J Rader; Susan Redline; Stephen S Rich; Jerome I Rotter; Herman A Taylor; Russell P Tracy; Ramachandran S Vasan; James G Wilson; Sekar Kathiresan; Richard R Fabsitz; Eric Boerwinkle; Stacey B Gabriel Journal: Circ Cardiovasc Genet Date: 2010-04-17
Authors: Fernanda Rebelo; Michael M Schlüssel; Juliana S Vaz; Ana Beatriz Franco-Sena; Thatiana J P Pinto; Francisco I Bastos; Amanda R A Adegboye; Gilberto Kac Journal: J Hypertens Date: 2013-01 Impact factor: 4.844
Authors: Kathryn J Gray; Vesela P Kovacheva; Hooman Mirzakhani; Andrew C Bjonnes; Berta Almoguera; Andrew T DeWan; Elizabeth W Triche; Audrey F Saftlas; Josephine Hoh; Dale L Bodian; Elisabeth Klein; Kathi C Huddleston; Sue Ann Ingles; Charles J Lockwood; Hakon Hakonarson; Thomas F McElrath; Jeffrey C Murray; Melissa L Wilson; Errol R Norwitz; S Ananth Karumanchi; Brian T Bateman; Brendan J Keating; Richa Saxena Journal: Hypertension Date: 2018-07-02 Impact factor: 10.190
Authors: K J Gray; V P Kovacheva; H Mirzakhani; A C Bjonnes; B Almoguera; M L Wilson; S A Ingles; C J Lockwood; H Hakonarson; T F McElrath; J C Murray; E R Norwitz; S A Karumanchi; B T Bateman; B J Keating; R Saxena Journal: BJOG Date: 2020-09-14 Impact factor: 6.531